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Abstract:
The aim of pharmacological therapy for asthma is to improve symptoms and lung
function and minimise the risk of asthma attacks. The intensity of treatment is based on
the level of asthma control and the potential risk of future deterioration. In the British
asthma guidelines, treatments are divided into Step One to Five, with each Step
signifying a need for an increase in therapy in response to symptoms or to prevent
exacerbations. Treatments comprise of inhaled or systemic medications. Inhaled
therapy includes short-acting and long-acting medication to improve symptoms and
inhaled corticosteroids which reduce airway inflammation. Systemic treatments include
medications which act on specific biological pathways, such as the leukotriene or IgE
pathways, or systemic corticosteroids. In choosing a particular therapy, treatment
benefits are balanced by the potential risks of medication-related adverse effects. This
review will provide a practical guide to the key pharmacological therapies for adult
asthma at Steps One to Five based on British guidelines and consider future options for
new treatments.
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Introduction
Pharmacological therapy is a key component of the management of people with
asthma.1 Current established treatments can be classified into two groups: medication
taken via the inhaled route and treatment taken via the systemic route (for example, oral,
intravenous, subcutaneous or intramuscular) [Table 1].2-4 Inhaled therapy includes
short-acting beta-agonists (SABA), which are used to provide short-term improvement
in symptoms, and inhaled corticosteroids (ICS), which suppress airway inflammation.
In addition, inhaled long-acting beta-agonists (LABA) are symptom-controller
medications that are used in combination with ICS. Systemic therapy for asthma
includes systemic corticosteroids,5 leukotriene receptor antagonists and more recently,
‘targeted’ therapy towards specific underlying biological processes, such as anti-IgE,
anti-IL5 and anti-IL13 [Table 2].
Treatment is generally tailored to the severity of underlying disease activity, usually
measured by a combination of symptoms, lung function and assessment of the risk of
adverse outcomes such as exacerbations, lung function decline or treatment-related
adverse effects.6 The intensity of the treatment, or treatment ‘Step’, reflects the
perceived level of current impairment or future risk of an adverse event such as a severe
exacerbation or diminished lung function. People are prescribed medications that range
from Step 1 (‘low’ intensity treatment) to Step 5 (‘high’ intensity treatment), with an
increase or decrease in Step based on reviewing the adherence and response to current
therapy, generally over a period of two to six months [Figure 1].4 There should
therefore be a close relationship between the assessment of current asthma control,
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identification of the risk of future adverse outcomes and the prescribed pharmacological
treatment Step.
The aim of this review is to provide a concise summary of the key pharmacological
therapy for adult asthma and to highlight emerging treatments that may be
recommended in the future. We will base our review on British asthma guidelines,4
supported by both the American3 and international2 asthma guidelines. We will focus
on the practical use of these treatments in the clinical setting, rather than on detailed
pharmacological mechanisms and biological modes of action, which are discussed
elsewhere.7
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Step 1: As-required short-acting beta-agonists
Step 1 therapy is generally recommended for people with very mild ‘intermittent’
asthma. Guidelines suggest that these people are characterised by intermittent, mild
symptoms, infrequent nocturnal awakening, normal lung function, and a low risk of
future adverse events.2-4 Common triggers for symptoms are exercise, allergens or
infections.8
People are offered symptomatic treatment in the form of inhaled SABAs, such as
salbutamol or terbutaline. These drugs have a rapid onset but short duration of action,
and act as bronchodilators. As-required SABA treatment is comparable to regular
SABA treatment but with lower drug exposure and is generally the preferred option.9
Future directions
The commencement of Step 1 therapy relies on establishing a diagnosis of probable
asthma together with an assessment of an adequate level of current control and low risk
of future exacerbations. In clinical practice, barriers exist to all of these processes. The
majority of people with mild intermittent asthma are seen in primary care, where access
to diagnostic aids, such as tests of atopy, airway inflammation and bronchial hyper-
responsiveness, may be poorly, if at all available. There is also variable use of available
tools, such as questionnaires used to assess asthma control10 and lung function testing.
In addition, it remains difficult to predict which individuals are at risk of future poor
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control or exacerbations.11 This can cause uncertainty in selecting those people who
could benefit from early commencement of regular preventer therapy.
Future work is likely to focus on more comprehensive initial evaluation of people
presenting with possible asthma, in order to confirm the diagnosis and help define
individual characteristics which can help to predict an increased risk of future adverse
outcomes. For example, early detection of uncontrolled eosinophilic airway
inflammation could help to identify individuals with an increased risk of severe
exacerbation.12 This information will then help to inform initial treatment choices, such
as the early use of ICS. Additionally, novel treatment strategies, such as the on-demand
use of combination ICS/fast-onset LABA inhalers in response to asthma symptoms,13
will provide further options for earlier ICS treatment in people with intermittent
symptoms. The focus of therapy at Step 1 will therefore move towards improved
identification of individuals at risk of poor control, and earlier exposure to ICS.
Step 2: Regular inhaled corticosteroid treatment
In people with persistent symptoms despite Step 1 therapy (e.g. nocturnal wakening,
regular need for SABA therapy), or in whom initial assessment suggests a greater risk
of future adverse outcomes (e.g. prior severe exacerbation, impaired lung function), the
standard approach is regular maintenance treatment with low-dose ICS and SABA for
relief of breakthrough symptoms.14 Corticosteroids act by inhibiting pro-inflammatory
cellular processes as well as having topical effects which may reduce airway
inflammation.15, 16 Treatment with ICS is associated with an improvement in symptoms
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and lung function17 and a reduction in exacerbations17, 18 and risk of death.19 ICS
treatment is generally prescribed twice daily and 400µg per day of beclometasone
dipropionate (BDP) (or equivalent) is a usual starting dose for mild to moderate asthma
severity.14 Most of the therapeutic benefit from ICS is attained at low-to-moderate
doses,20, 21 though people with more severe disease (e.g. frequent exacerbations) may
benefit from higher doses.22 In corticosteroid-naive individuals with mild asthma,
initial use of combination ICS/LABA therapy offers no advantages compared to ICS
alone.18, 23
ICS is available in a range of formulations, with variability in pharmacological
properties and drug delivery devices.24 Common adverse effects include dysphonia and
orophayngeal candidiasis, and use of spacers together with advice on mouth rinsing
after dosing may help reduce this effect.3 Systemic side effects have been associated
with ICS therapy,25 usually with high-dose/long-term use, though the risk/benefit profile
generally favours their use.
Alternative preventer therapy at Step 2 includes the use of oral leukotriene receptor
antagonists. These drugs have both bronchodilator and anti-inflammatory properties,26
and may offer an alternative for some people with mild asthma.27 However, current
recommendations are that ICS remain the preferred option for use as sole maintenance
therapy.28
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Future directions
Poor adherence to maintenance ICS therapy is a key factor contributing to the risk of
future severe exacerbations.29, 30 Thus, people with asthma at Step 2 may remain poorly
controlled and ‘at risk’ because they perceive little symptomatic benefit day-to-day
from their prescribed ICS therapy and so can underuse their maintenance inhaler and
over-rely on their reliever SABA inhaler. Two strategies have been studied which aim
to promote exposure to ICS: intermittent ‘as-needed’ ICS treatment and as-needed
combination ICS plus SABA treatment.
In adults, as-needed ICS used in response to worsening symptoms provided comparable
improvements in morning peak expiratory flow rate compared to regular ICS therapy, at
markedly reduced overall ICS exposure.31 However, participants in the regular ICS
group had significantly greater improvements in asthma symptoms, pre-bronchodilator
FEV1 and airway inflammatory measures than the as-needed group.31 Asthma quality
of life scores and exacerbation rates were similar between these two groups.31 These
findings have led to differing opinions regarding the role of as-needed ICS therapy in
mild asthma.32, 33 At present, there is insufficient evidence to recommend the routine
use of the as-needed ICS regimen34 and further study in real-world trials is required.35
An alternative strategy uses symptom-driven as-required ICS/SABA (in a combination
inhaler)36 or ICS+SABA (taken via separate inhalers).37 The advantage of this strategy
is that people are exposed to ICS at the time of SABA use, thus providing both
immediate bronchodilation and anti-inflammatory treatment during worsening asthma.
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These studies demonstrated that the symptom-driven approach provided similar
improvements in asthma symptoms, lung function and exacerbations at reduced ICS
exposure compared to regular ICS therapy.36, 37 However, combination ICS/SABA
inhalers are currently not available in the UK and the use of separate ICS+SABA
inhalers is likely to be impractical in the clinical setting.
Trials using the as-needed approach, but using combination ICS/fast-onset LABA
inhalers, will provide further information on the utility of this approach using inhalers
that are available to prescribe in the clinical setting.38 Results from real-world trials in
particular, and utilising electronic monitoring to describe patterns of medication use,39
will help guide clinicians as to the risks versus benefits of this approach in adults with
mild persistent asthma.
Step 3: Add-on treatments
International guidelines recommend the addition of a LABA to low-dose ICS as the
preferred option for Step 3 maintenance treatment, with SABA for relief of symptoms.2,
4 There are however a number of alternative strategies available at Step 3.
A major asthma study showed that the combination of low-dose ICS (200µg
budesonide/day) and LABA (formoterol) significantly reduced severe exacerbations
compared to low-dose ICS alone.22 Low-dose ICS and LABA in combination were also
superior to a four-fold higher dose of ICS (800µg budesonide/day) in improving asthma
symptoms.22
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However, in this study, higher-dose budesonide treatment resulted in significantly
greater reductions in asthma exacerbations compared to combination low-dose ICS and
LABA treatment.22 Therefore, an alternative option at Step 3 is to increase the dose of
ICS to 800µg/day BDP (or equivalent) instead of using a LABA with low-dose ICS.2, 3
Although this is not the preferred strategy in the UK,4 this option remains available in
people with asthma who have no improvement following the initial add-in of LABA
therapy.
Greatest improvements (reductions) in exacerbations in this study were achieved with
the higher-dose ICS and LABA in combination. 22 Individuals who are considered at
higher risk for poor control and asthma exacerbations can benefit from the use of
higher-dose (up to 800µg/day of BDP or equivalent) combination ICS/LABA
therapy.22,40
In clinical practice, use of a combination ICS/LABA inhaler is likely to encourage
adherence to ICS41, 42 and avoid the risk of LABA monotherapy.43 British guidelines
recommend this practice as the preferred option when people are prescribed these two
classes of drugs.4 In recent years, there have been concerns raised regarding the safety
of LABAs44 and large-scale studies are underway to further investigate this issue.45
Another option at Step 3 is the use of a single combination ICS/fast-onset LABA
inhaler as regular maintenance therapy, but with additional doses of the same inhaler
also taken for relief of symptoms.46-49 This treatment plan, called Single combination
ICS/LABA inhaler as Maintenance And Reliever Therapy (SMART), has the advantage
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of providing individuals with a dose of ICS every time their inhaler is used for relief of
symptoms. This has the dual effect of reducing non-adherence to ICS and allowing
higher doses of ICS to be delivered at the time of worsening symptoms.48 This regimen
significantly reduces severe exacerbations of asthma by around 50% compared to the
same fixed dose of maintenance ICS/LABA therapy with SABA for relief.46-49 SMART
can be considered the preferred option in adults at risk of future severe exacerbations.2,50
An alternative to the addition of LABA is the addition of a leukotriene receptor
antagonist to ICS treatment. A recent study has suggested that the add-on of leukotriene
receptor antagonists may promote adherence to treatment compared to the addition of a
LABA in a real-world setting.27 However, the most recent Cochrane review suggests
the LABAs provide greater advantages in terms of reducing severe exacerbations,51 and
so they remain the preferred add-on treatment at Step 3.4
Future directions
Future research at Step 3 and above is likely to focus on the use of therapy guided by
underlying disease biological processes.52-54 In this regard, the application of findings
from cluster analyses can help to delineate phenotypic characteristics.55, 56 For instance,
recognition of the eosinophilic/allergic endotype will help to predict improved ICS
responsiveness,57 whereas a favourable response to leukotriene receptor antagonist
therapy could be suggested by an eosinophilic endotype characterised by altered
eicosanoid metabolism.52, 58, 59 Study of genetic variations in the beta-adrenoceptor
protein and risk of adverse outcomes may help to inform clinicians as to particular
CRD paper 04112014 Page 12 of 33
individuals in whom LABA therapy may be of diminished value.60 The application of
pharmacogenetics to help predict response to clinical treatments could also be valuable
for other classes of asthma medication.61
A recent trial has investigated patient use of electronic monitors which measure
ICS/LABA inhaler use and provide medication reminders for missed doses as a method
to improve medication adherence.62 This trial was conducted in primary care and 32%
of participants had received at least one course of oral corticosteroids in the prior year
for asthma. Participants randomised to receive medication reminders had significantly
greater ICS/LABA adherence at six months (60% of daily prescribed doses taken)
compared to participants who were electronically monitored without receiving
reminders (29% of daily prescribed doses taken). However, there were no significant
differences between groups in asthma control or severe exacerbations. Future work will
focus on the utility of electronic monitoring technology to improve inhaler adherence
and clinical outcomes in selected cases,63 such as individuals at risk of asthma
exacerbations or people with unrecognised poor adherence under consideration for
novel biological treatments for severe asthma.64
Finally, novel inhaled LABA and ICS drugs are emerging that will provide greater
choice for use with adults at Step 3 and above. These include newer ICS/LABA
combinations,65, 66 as well as ICS in combination with 24-hour acting LABA which can
allow once-daily inhaled treatment.67
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Step 4: High-dose ICS with other controller medications
There are few data on the optimal strategies at Steps 4 and 5. Options are therefore
based on individual discussions around the risks versus benefits of a trial of additional
treatments. In people with asthma in whom add-on therapy provides no benefit, or
results in side effects, then the usual action is to return to the previous regimen and
consider an alternative add-on option. At Steps 4 and 5, it remains important to
consider adherence to treatment, avoidance of asthma triggers, assessment for co-
existing disease and psychological factors, all of which may affect asthma control.
An initial option is to increase the ICS dose to up to 2000µg/day (BDP or equivalent, in
addition to LABA treatment), recognising that the risk of potential side effects of ICS
may be greater than the benefits at these doses.68 Alternative options include the
addition of a leukotriene receptor antagonist, oral theophylline or oral beta-agonist
tablets.4
In selected people at Step 4 with allergic asthma who require frequent courses of oral
corticosteroids (four or more in the prior year), The National Institute for Health and
Care Excellence (NICE) has approved the use of omalizumab, a monoclonal antibody
against IgE.69 This treatment is also approved at Step 5 and there are specific eligibility
criteria regarding IgE levels and lung function. Omalizumab is administered in
specialist centres by subcutaneous injection every two to four weeks, usually for a
period of four to six months, at which point reassessment of the clinical benefit is
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required. For some adults, this treatment is effective in reducing severe asthma
exacerbations.70, 71
Future directions
A trial in people poorly controlled on moderate-to-high dose ICS plus LABA therapy
has suggested that the addition of the long-acting muscarinic antagonist tiotropium (via
soft mist inhaler) reduces the risk of a severe exacerbation by 21% compared to
placebo.72 Participants in this trial had persistent airflow limitation, though potentially
eligible participants using maintenance oral corticosteroids at more than 5 mg/day were
excluded.72 Tiotropium has recently become approved for maintenance asthma
treatment in Europe. In the UK, a therapeutic trial can be considered in people on
medium-to-high dose (≥800µg/day of budesonide or equivalent) ICS/LABA with at 
least one severe exacerbation in the previous year. Additionally, a recent meta-analysis
has indicated that tiotropium may be useful as an alternative to salmeterol add-on
therapy in poorly-controlled individuals on medium-to-high dose ICS,73 although this
indication remains unlicensed currently.
Macrolide antibiotics, such as azithromycin or clarithromycin, have also been used for
their antibiotic and anti-inflammatory properties in asthma.74 Their use may be of
particular benefit in reducing exacerbations in severe neutrophilic asthma.75 However,
further long-term study of the impact of treatment on airway microbiota,76
cardiovascular risk and mechanisms of action74 are required.
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Step 5: Maintenance oral corticosteroids
Step 5 is defined by the requirement for maintenance oral corticosteroid treatment. This
is usually reserved for people requiring frequent short courses of oral corticosteroids for
persistently uncontrolled asthma despite other treatments above.77 The aim is to titrate
treatment to the lowest maintenance dose that achieves asthma stability and to monitor
or treat for steroid-related adverse effects.78
Methotrexate, azathioprine, ciclosporin and gold have been used as corticosteroid-
sparing agents, but these drugs are associated with significant side effects and their
routine use is not supported by the findings from Cochrane reviews.79-82
Future directions
Recent work has focussed on the use of biological agents targeted at Th2-driven
cytokines, such as IL-4,83 IL-584-86and IL-13.87 These drugs have generally been tested
in rigorously conducted clinical trials in carefully selected participants, and have shown
promising results. Most recently, two studies have demonstrated the efficacy of
subcutaneous mepolizumab (a monoclonal antibody against IL-5) in reducing asthma
exacerbations in severe eosinophilic asthma,84, 85 and this treatment will likely become
available for use in clinical practice in the near future. Further work is underway to
identify biological and clinical characteristics that may help to predict favourable
treatment response with other novel agents.88, 89
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Step up and Step down of therapy
Step up of therapy is generally considered if there is evidence of persistent symptoms,
diminished lung function or ongoing airway inflammation after a period of two to three
months on the current treatment regimen.90 Prior to Step up, it is important to review
the validity of the original diagnosis of asthma, because misdiagnosis, or the presence of
co-existing conditions requiring their own specific treatments, may help to explain the
incomplete response to current therapy. Review of adherence to treatment, triggers for
worsening asthma and inhaler technique2 are other factors that should be considered
with every change in therapy.
Step down of treatment may be considered after three to six months of clinical stability,
with the intention of maintaining asthma control at a reduced medication burden. There
are a variety of options available,2 including ICS dose reduction,91 use of a lower dose
combination ICS/LABA preparation,92 and change from twice daily to once daily
dosing. Recently, the US Food and Drug Administration (FDA) has recommended that
once asthma control is achieved, LABAs should be withdrawn and treatment
maintained with ‘controller medication such as ICS’.45 However, this approach can lead
to loss of asthma control, compared with continuation of ICS/LABA therapy,93 and so
may not be appropriate for individuals at risk of future asthma exacerbations.94
In general, a 25-50% ICS dose reduction is considered safe for most well-controlled
people with asthma.2 One caveat is that in adults who are stable on a low maintenance
dose of ICS, there is an increased risk of future asthma exacerbation after ICS cessation
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compared to continuation of ICS.95 In these individuals, complete cessation of ICS
therapy is therefore not advised.2
Factors determining choice of inhaler
The key factors that determine the choice of inhaler device are individual preference,
acceptable inhaler technique for the chosen device and local availability and cost. In
general, metered-dose inhalers are considered first-line for both preventer96 and
reliever97 inhaler prescription. Inhaler use training helps to improve technique98 and is
an important factor in helping to optimise drug delivery to the lungs.99 However, three
situations when specific formulations may be selected are: for improving drug
deposition in the small (<2 mm) airways; reduced exposure to the systemic effect of
ICS; and, for reduction in risk of ICS-associated pneumonia and lower respiratory tract
infection.
Inflammation occurring in the distal small airways of the bronchial tree may contribute
to the clinical features of asthma, such as poor control and airway hyper-
responsiveness.100 Newer inhaler devices, which generate smaller particle aerosols, can
allow improved drug deposition in the small airways15 and there is increasing evidence
to suggest that this may help to improve asthma control.101 However, challenges remain
in identifying small airways dysfunction in a clinical setting,15, 100 limiting the
widespread use of these inhalers. One approach is to switch to a small particle
formulation in the setting of persistent poor control despite adequate inhaler technique
(and adherence) with a standard large particle inhaler.
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Systemic effects of ICS may be reduced by specific pharmacological properties of the
drug.24 For example, ciclesonide is a pro-drug which is converted to an active
metabolite in the lung and which has limited oral bioavailability after inhalation.102
Mometasone is another ICS with limited systemic bioavailability, because most of the
swallowed dose is excreted unchanged and any absorbed drug undergoes liver
metabolism into less active compounds.103 However, the superiority of these drugs over
other ICS formulations prescribed at low-to-medium daily doses has not been
established and in clinical practice, they remain an option for selected cases only.
Finally, there is emerging evidence to suggest that high-dose ICS use is associated with
an increased risk of pneumonia or lower respiratory tract infection and that this risk is
enhanced by use of certain ICS formulations, particularly those containing high-dose
fluticasone, in comparison to budesonide or beclomethasone.104 In people with asthma
with recurrent respiratory infections, consideration should be given to reviewing the
choice and dose of the prescribed ICS treatment.
Influenza vaccination and smoking cessation
Viral infections, including those caused by influenza, are associated with asthma
exacerbations in observational studies.105, 106 Although there is insufficient evidence to
demonstrate a reduction in exacerbations as a result of influenza vaccination,107 current
UK guidelines recommend influenza immunisation in people with chronic asthma in
order to help reduce the potential morbidity associated with deteriorating asthma
control.108
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Current smoking is associated with increased odds of asthma hospitalisation, greater
asthma severity and worse quality of life compared to never smoking.109 Smokers may
also have a diminished response to ICS compared to non-smokers.110 Support to access
smoking cessation services should be considered for all people with asthma.2
Conclusion
Pharmacological therapy for asthma is prescribed based on the level of current
symptoms and lung function together with an assessment of the risk of future adverse
events such as exacerbations. The intensity of the treatment ranges from as-needed use
of short-acting reliever therapy to the use of systemic anti-inflammatory therapy. At
each treatment Step, adherence to medication, occurrence of side effects and assessment
of co-existing conditions and triggers should be undertaken. In this review, we have
provided a practical summary of the current standard pharmacological management of
adult asthma based on British guidelines and suggested emerging treatments which may
be recommended for use in the future.
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Table 1: Currently approved pharmacological therapy for adult asthma
Treatment Category Treatment Step
Short-acting beta-
agonists (SABA)
Inhaled bronchodilator symptom reliever* 1 to 5
Inhaled corticosteroids
(ICS)
Anti-inflammatory preventer therapy † 2 to 5
Sodium chromoglycate
or Nedocromil sodium
Inhaled mast cell stabiliser 2 to 5
Long-acting beta-agonist
(LABA)
Inhaled bronchodilator symptom controller ± 3 to 5
ICS/fast-onset LABA
maintenance and reliever
therapy
Regular preventer ICS/LABA therapy with
added doses for relief of symptoms #
3
Leukotriene receptor
antagonist
Oral smooth muscle relaxant and anti-
inflammatory treatment
3 to 5
Theophylline Oral anti-inflammatory treatment 3 to 5
Bambuterol Oral slow-release beta-2 agonist 3 to 5
Tiotropium (via soft mist
inhaler)
Long-acting muscarinic antagonist
bronchodilator
4 to 5
Omalizumab Anti-IgE monoclonal antibody 4 to 5
Maintenance oral
corticosteroids
Systemic anti-inflammatory treatment 5
* Terbutaline is available in oral and parenteral preparations
† Low-medium adult doses are: 200-800µg/day of beclometasone dipropionate or
budesonide; 100-500µg/day of fluticasone propionate; 400µg/day of mometasone furoate.
High adult doses are: >800-2000µg/day of beclometasone dipropionate or budesonide; >500-
1000µg/day of fluticasone propionate; >400-800µg/day of mometasone furoate.
± Only used in combination with ICS, preferably in a single combination ICS/LABA inhaler
# Licensed for use with 100/6µg or 200/6µg budesonide/formoterol dry powder inhaler or
100/6µg beclometasone/formoterol metered dose inhaler
Table 2: Emerging therapies for adult asthma
Treatment Category Treatment Step
‘As-needed’ ICS/fast-
onset LABA inhaler
Inhaled treatment in response to
symptoms
1 to 2
ICS/24-hour acting
LABA
Combination ICS and ultra-LABA 3+
Azithromycin Oral antibiotic with anti-inflammatory
effects
4 to 5
Anti IL-4, IL-5 and IL-
13
Systemic biologic treatment 4 to 5
Figure 1: Treatment Steps in adult asthma [This figure is reproduced from the 2014 BTS/SIGN British guideline on the management of
asthma, by kind permission of the Scottish Intercollegiate Guidelines Network]4
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